drugset / Trial / NCT00401115

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

NCT00401115

Phase 1 Completed 50 enrolled Santen Inc. MacuSight, Inc. · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy

Timeline

Start
2006-09
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule Other